Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from Needham & Company LLC

Axsome Therapeutics (NASDAQ:AXSM)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a report released on Monday,Benzinga reports. They currently have a $225.00 target price on the stock. Needham & Company LLC’s price target points to a potential upside of 32.39% from the stock’s current price.

AXSM has been the topic of several other reports. Royal Bank Of Canada increased their price objective on Axsome Therapeutics from $212.00 to $219.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. UBS Group upped their target price on shares of Axsome Therapeutics from $163.00 to $248.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Wells Fargo & Company boosted their price target on shares of Axsome Therapeutics from $157.00 to $193.00 and gave the stock an “overweight” rating in a report on Tuesday, January 13th. Morgan Stanley lowered shares of Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a report on Thursday, January 8th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Axsome Therapeutics in a report on Thursday, January 29th. Seventeen investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $216.12.

Axsome Therapeutics Price Performance

AXSM opened at $169.95 on Monday. The stock’s 50-day moving average price is $174.91 and its 200 day moving average price is $145.40. Axsome Therapeutics has a 12-month low of $86.99 and a 12-month high of $191.50. The firm has a market cap of $8.57 billion, a price-to-earnings ratio of -46.06, a PEG ratio of 12.57 and a beta of 0.40. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.14. The company had revenue of $196.00 million for the quarter, compared to analyst estimates of $191.33 million. Axsome Therapeutics had a negative net margin of 28.69% and a negative return on equity of 251.47%. Axsome Therapeutics’s revenue for the quarter was up 65.0% compared to the same quarter last year. As a group, sell-side analysts expect that Axsome Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark E. Saad sold 37,577 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the completion of the sale, the director directly owned 10,002 shares of the company’s stock, valued at $1,652,130.36. This represents a 78.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ari Maizel sold 7,500 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total value of $1,383,300.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 308,874 shares of company stock worth $51,390,805 in the last 90 days. Company insiders own 22.40% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors have recently bought and sold shares of the company. Versant Capital Management Inc lifted its stake in shares of Axsome Therapeutics by 20,300.0% in the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after acquiring an additional 203 shares during the period. Kemnay Advisory Services Inc. purchased a new position in Axsome Therapeutics during the fourth quarter worth about $31,000. First Horizon Corp purchased a new stake in shares of Axsome Therapeutics in the third quarter valued at approximately $34,000. Optiver Holding B.V. grew its holdings in Axsome Therapeutics by 82.3% during the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after acquiring an additional 130 shares during the period. Finally, Ameriflex Group Inc. purchased a new position in Axsome Therapeutics in the fourth quarter worth $37,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Revenue and commercial strength — Q4 sales jumped roughly 65% year‑over‑year and full‑year 2025 revenue rose strongly, led by Auvelity and Sunosi, beating consensus revenue estimates and showing solid commercial traction. AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
• Positive Sentiment: Pipeline progress — Axsome dosed the first patient in the CLARITY Phase 3 trial of solriamfetol for MDD with excessive daytime sleepiness, adding a near‑term clinical catalyst. Axsome Therapeutics Initiates CLARITY Phase 3 Trial
• Positive Sentiment: Analyst support — Needham reaffirmed a Buy and set a $225 price target, signaling continued bull case and upside potential. Benzinga coverage of Needham rating
• Neutral Sentiment: Earnings materials and call — Management released the Q4 / FY2025 results, slide deck and earnings call transcript; these provide detail behind the revenue beat and guidance/comments for investors to review. Axsome press release / slide deck
• Neutral Sentiment: Mixed EPS reporting — several outlets summarized Q4 results and call highlights (transcript and summaries available), useful for investors but containing varying EPS figures across reports. AXSM Q4 2025 Earnings Call Highlights
• Negative Sentiment: Profitability and accounting headlines — despite revenue strength, Axsome remains loss‑making (negative net margins and a large negative ROE); some reports flagged a wider per‑share loss in certain metrics, creating near‑term investor concern. Axsome Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Valuation and pipeline skepticism — some analysts and commentators argue the pipeline may be overvalued and commercial uptake risks remain, tempering enthusiasm despite upside price targets. Axsome: Q4 Earnings Review — Pipeline May Be Overvalued

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.